Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

163.50p
   
  • Change Today:
    -1.90p
  • 52 Week High: 224.66p
  • 52 Week Low: 77.00p
  • Currency: UK Pounds
  • Shares Issued: 201.34m
  • Volume: 1,126,401
  • Market Cap: £329.19m
  • RiskGrade: 510

Synairgen confirms start of dosing in Covid-19 trial

By Josh White

Date: Monday 15 Feb 2021

LONDON (ShareCast) - (Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.
The AIM-traded firm said on 25 January that 'ACTIV' is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising Covid-19 treatments and vaccines.

It said ACTIV-2 was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the US National Institutes of Health, and was led by the NIAID-funded AIDS Clinical Trials Group.

If an investigational agent showed promise by demonstrating safety and reducing Covid-19 symptoms through 28 days following administration, the ACTIV-2 trial was designed to expand seamlessly from a phase 2 to a phase 3 study to gather additional critical data from a larger pool of volunteers without delay.

Phase 2 sub-studies enrol up to 220 volunteers, while exact enrolment size of phase 3 sub-studies would vary depending on the mode of administration of the investigational agent.

The adaptive nature of the ACTIV-2 trial would allow for comparison of multiple interventions with a shared group of placebo recipients.

In addition to safety and symptomatic efficacy signals, the sub-studies in ACTIV-2 would assess whether an investigational agent could reduce the amount of SARS-CoV-2 virus detectable in the nasopharynx.

"With mutations of Covid-19 now emerging, and the concern that mutations may render the vaccines less effective, the need for broad spectrum treatment options remains very high," said chief executive officer Richard Marsden.

"Our product is a potentially effective treatment as it is a virus agnostic and, we believe, strain agnostic antiviral, which is easy to use in the hospital or home setting."

At 1149 GMT, shares in Synairgen were up 1.25% at 190.34p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Synairgen Market Data

Currency UK Pounds
Share Price 163.50p
Change Today -1.90p
% Change -1.15 %
52 Week High 224.66p
52 Week Low 77.00p
Volume 1,126,401
Shares Issued 201.34m
Market Cap £329.19m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.13% above the market average48.13% above the market average48.13% above the market average48.13% above the market average48.13% above the market average
92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average
Price Trend
4.26% below the market average4.26% below the market average4.26% below the market average4.26% below the market average4.26% below the market average
16.13% above the sector average16.13% above the sector average16.13% above the sector average16.13% above the sector average16.13% above the sector average
Income
4.86% above the market average4.86% above the market average4.86% above the market average4.86% above the market average4.86% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 21-Sep-2021

Time Volume / Share Price
16:35 8,082 @ 163.50p
16:29 14 @ 161.50p
16:29 27 @ 161.50p
16:29 11 @ 161.50p
16:29 531 @ 161.60p

Synairgen Key Personnel

CEO Richard J Marsden
Finance Director John C Ward

Top of Page